NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading PACB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a speculative growth investment with a medium confidence level. The company is currently loss-making but shows signs of progress in revenue and margin improvement, making it a watchful situation for investors.
The market appears to have priced in a justified valuation, with PACB being seen as cheap compared to its peers. There is a low fragility tier, indicating that the stock is not overly sensitive to immediate changes.
Management is focused on achieving revenue guidance of $165M to $175M for 2026 and improving gross profit margins. Recent results show a positive trajectory in reducing operating losses, although the company remains volatile.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could provide a favorable environment for PACB. Conversely, any negative guidance from these peers could impact PACB negatively.
Overall, PACB's prospects depend on its ability to meet management's revenue goals and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this revenue target shows growth momentum. It is key for investor confidence.
Confirms:Q2 revenue reported between $165M and $175M.
Disproves:Q2 revenue falls below $165M.
Why it matters: Earnings results will provide insights into revenue and margin progress.
Confirms one read:Earnings report shows strong revenue and margin improvements.
Confirms the other:The earnings report has weak results.
Why it matters: Meeting revenue guidance is key to achieving the full-year target of $165M to $175M.
Confirms:Q2 2026 revenue is $41.8 million or more. This shows growth is continuing.
Disproves:Q2 2026 revenue is less than $41.8 million. This shows challenges in meeting goals.
Why it matters: Cutting losses shows the company is working better. This is key for lasting success.
Confirms:Operating losses decrease further from -$8.36M in 2026-Q1.
Disproves:Operating losses increase or stay the same.
Why it matters: Lower operating losses mean better cost control. This can make investors more positive.
Confirms:Operating losses decrease by at least 10% compared to Q1.
Disproves:Operating losses increase or stay the same.
Why it matters: Better margins mean lower costs and better operations. This helps make more money.
Confirms:Gross profit margin is over 37% in Q2 2026. This shows good cost control.
Disproves:Gross profit margin is at or below 37%. This shows ongoing cost issues.
Why it matters: Cutting operating losses is important. It helps finances and builds investor trust.
Confirms:Operating losses are below $8 million in Q2 2026. This shows a positive trend.
Disproves:Operating losses are at or above $8 million. This suggests ongoing financial problems.
